A possible biochemical mode of action for benzimidazole anthelmintics.
Albendazole (ABZ), cambendazole (CBZ), oxibendazole (OBZ), and thiabendazole (TBZ) are potent, orally active, broad spectrum anthelmintics widely used in human and veterinary medicine. As members of the benzimidazole series, they are closely related chemically, and it is likely that they exert their anthelmintic effects in an identical fashion. We have examined the effects of these anthelmintics on the electrical resistance of planar bimolecular lipid membranes and compared the results with those obtained with a known uncoupler, 2,4-dinitrophenol (2,4-DNP). All drugs tested markedly reduced membrane resistance at concentrations lower than 0.1 microM and were better proton conductors than 2,4-DNP by at least an order of magnitude. The sequence of proton conducting efficiency was ABZ greater than OBZ greater than TBZ greater than CBZ greater than 2,4-DNP. From 1 to 40 microM, ABZ and CBZ substantially decreased P/O (phosphorous/oxygen) ratios in coupled rat liver mitochondria in a concentration-dependent fashion using beta-hydroxybutyrate as the substrate. 2,4-DNP was also shown to decrease P/O ratios, but less effectively than the benzimidazole anthelmintics. These experiments indicate that the benzimidazole anthelmintics are lipid-soluble proton conductors that are effective in artificial (phospholipid bilayer) and natural (rat liver mitochondria) membrane systems. Dissipation of the transmembrane proton gradient should result in diminished levels of cellular ATP. In vivo treatment with a therapeutically effective dose of ABZ caused a severe disturbance in the energy balance of Hymenolepis diminuta; this was evident from a distinct drop in ATP levels, and from a decline in the ATP/ADP ratios, adenylate energy charge (AEC) and available adenylate energy (AAE) values.(ABSTRACT TRUNCATED AT 250 WORDS)
McCracken
R O
RO
Indiana University-Purdue University, Indianapolis 46205.
Stillwell
W H
WH
D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D006925:Hymenolepiasis / Q000188:drug therapy*; D008297:Male; D008563:Membrane Lipids / Q000502:physiology; D008567:Membranes, Artificial; D008930:Mitochondria, Liver / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains
D000871:Anthelmintics; D001562:Benzimidazoles; D008563:Membrane Lipids; D008567:Membranes, Artificial